ArmonAir Digihaler
ArmonAir Digihaler is a prescription inhalation powder containing fluticasone propionate, an inhaled corticosteroid (ICS) designed to reduce inflammation in the airways. It features a built-in electronic sensor that detects inhaler use, measures inspiratory flow rate, and transmits this data to a companion mobile application via Bluetooth.
Dosage by Body Weight
For oral inhalation only. The starting dosage is based on prior asthma therapy and disease severity. The recommended dose is 1 inhalation of 55 mcg, 113 mcg, or 232 mcg twice daily, approximately 12 hours apart. Patients should rinse their mouth with water without swallowing after each inhalation to prevent oral thrush.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- Do not use
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients under 12 years of age.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- Do not use
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients under 12 years of age.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- Do not use
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients under 12 years of age.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- Do not use
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients under 12 years of age.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- Do not use
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients under 12 years of age.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | Do not use | Safety and effectiveness have not been established in pediatric patients under 12 years of age. |
| 5-7 kg | Not recommended | Do not use | Safety and effectiveness have not been established in pediatric patients under 12 years of age. |
| 8-10 kg | Not recommended | Do not use | Safety and effectiveness have not been established in pediatric patients under 12 years of age. |
| 11-15 kg | Not recommended | Do not use | Safety and effectiveness have not been established in pediatric patients under 12 years of age. |
| 16-20 kg | Not recommended | Do not use | Safety and effectiveness have not been established in pediatric patients under 12 years of age. |
Formulation
Purpose
Long-term maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. It is not indicated for the relief of acute bronchospasm.
Generic Name
Fluticasone propionateScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.